Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

"Complete Response" Reg Seeks Comment On Public Disclosure Of NDAs

This article was originally published in The Pink Sheet Daily

Executive Summary

The proposed rule would allow FDA to disclose the existence of an application once the sponsor has publicly disclosed it or after issuance of an approval or tentative approvable letter. The rule eliminates the use of "approvable" and "not approvable" letters.
Advertisement

Related Content

FDA Rejects “Approvable” And “Not Approvable” Letters
FDA Rejects “Approvable” And “Not Approvable” Letters
FDA 2004 Reg Agenda Includes "Complete Response" Rule, Electronic Drug Listing
FDA 2004 Reg Agenda Includes "Complete Response" Rule, Electronic Drug Listing

Topics

Advertisement
UsernamePublicRestriction

Register

PS060024

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel